Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs CYP2C19 Inhibitors (Moderate) |
Security Level |
 |
Mechanism |
CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates. |
Management |
Monitor therapy |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs CYP2C19 Inhibitors (Moderate)
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs CYP2C19 Inhibitors (Moderate) Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of CYP2C19 Inhibitors (Moderate)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.